The Drugging Autophagy Summit Goes Online for 2020
The Drugging Autophagy Summit goes online for 2020
Drug Discovery has been rocked by Covid-19 but as an industry, we cannot afford to put things on hold.
The Drugging Autophagy Summit has been completely re-engineered to deliver the best networking experience together with exciting new learning opportunities.
The agenda is purposely built to provide an engaging and interactive learning experience. Through integrated polls, open discussions, Q&A with speakers, and more, you will be able to accelerate your knowledge of how to drug autophagy-driven diseases in just two days. The ability to actively or passively be involved in these learning opportunities is yours!
Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join custom-built sessions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. The Drugging Autophagy Summit will enable you to meet more leaders from across the industry than ever before!
The Digital Platform lets you create your own personal agenda. You can attend live sessions, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.
The Drugging Autophagy Summit, brings together industry and academics in a unique format. It is a perfect place to share findings across disciplines, and accelerate the pace of drug discovery in the autophagy field.
The Drugging Autophagy Summit will bring together scientists and physicians in the public and private sector to discuss how best to target autophagy and in what disease indications.
Rapid advances in our understanding of autophagy provide a tremendous opportunity to take the field to the next level by developing novel strategies to deliberately manipulate autophagy to treat or prevent disease. By discussing the pros and cons of these approaches, this Summit will provide a great space to push these ideas forward.
Expert Speaker Faculty
Alec Kimmelman, M.D., Ph.D. is Professor and Chair of the Department of Radiation Oncology at NYU Langone Medical Center and a member of the Perlmutter Cancer Center at NYU. His laboratory has made seminal contributions to our understanding of pancreatic cancer – the fourth leading cause of cancer death in the US. In particular, recent work from his lab has established that pancreatic tumors rely on autophagy (“self-eating”) for proper growth. His research has elucidated unique metabolic pathways in pancreatic cancer and has identified how the Kras oncogene can re-wire the metabolism of these tumors.This body of work has served to define the metabolic landscape of pancreatic cancer and has paved the way for multiple clinical trials in this disease.
His own research has been published in many prestigious journals, including Cell, Science, Nature, Cancer Cell, Cancer Discovery, and Genes & Development. He has received numerous honors and awards, including the Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research from Columbia University for the researcher who has made the most significant contribution to pancreatic cancer research and he was elected to the American Society of Clinical Investigation.
Magdalene Moran, PhD, is a leading researcher in drug discovery with particular expertise in novel ion channels. Prior to joining Caraway Therapeutics, Dr. Moran spent over 15 years at Hydra Biosciences, where she was SVP of Biology. She has PhD in Neurobiology from Harvard University (Lab of David Clapham) and a BA in biology with a concentration in neuroscience from Williams College.
Dr. Amaravadi completed training at Columbia University, Johns Hopkins University, the Brigham and Women’s Hospital, and University of Pennsylvania. He was one of the first to demonstrate that targeting autophagy can augment cancer therapy in animal models. He has translated this finding into nearly a dozen clinical trials testing hydroxychloroquine (HCQ) as a possible anticancer agent in multiple cancers. With Dr. Jeffrey Winkler at UPENN he has developed a series of next generation chloroquine derivatives, and identified their molecular target. He is an Associate Editor for the journal Autophagy, and has been the lead organizer for the first two Autophagy and Cancer Banbury meetings in 2016 and 2018. He is co-Founder of Pinpoint Therapeutics and serves as an advisor to multiple drug development programs.
Daniel L. Flynn, PhD is Founder and Chief Scientific Officer of Deciphera Pharmaceuticals, a company he founded in 2003. His present research passion at Deciphera is in the area of small molecule kinase modulation through control of kinase conformational shape. This platform, called switch control inhibition, has been utilized at Deciphera to produce multiple drugs, 3 of which are currently in clinical development. Deciphera’s research in oncology has focused on tumor driver mutations, cancer cell metabolism, cancer immunotherapy, and the tumor microenvironment. Deciphera’s clinical stage drug pipeline includes DCC-2618, rebastinib, and DCC-3014. The ULK inhibitor DCC-3116 is currently in IND-enabling development.
Dan received a B.S. in Pharmacy from the University of Kansas in 1977, and then stayed at KU to receive his PhD in medicinal chemistry in 1981. After completing a post-doctorate in synthetic organic chemistry at Indiana University, he joined Warner-Lambert/Parke Davis Pharmaceuticals in Ann Arbor, Michigan, in 1983. From 1988 to 2002, Dan held positions in Searle Pharmaceuticals in Skokie, IL and later St. Louis, MO, Amgen, Inc in Thousand Oaks, CA, and Millennium Pharmaceuticals in Cambridge, MA. Dan is an Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the National Chair for the Division of Medicinal Chemistry of the American Chemical Society. Dan was inducted as an American Chemical Society Fellow in 2013. Dan has authored or co-authored over 100 publications in peer-reviewed journals and has been named an inventor on over 70 patents during his career.
Peter is a recognized industry leader in drug discovery, having spent 15 years at Sanofi, most recently as Global Head of External Innovation, Drug Discovery. Prior to his business development role, he led global medicinal and automated chemistry, natural product and antibody drug conjugate departments across Germany, France, and the US, with divisions of more than 100 international FTEs, and has contributed to the advancement of many projects into clinical development across multiple therapeutic areas. He started his career at AstraZeneca with a decade of leading medicinal chemistry teams in the respiratory and inflammation disease areas. His academic career spans postdoctoral positions with Prof Amos B. Smith III and Prof Ralph Hirschmann at the University of Pennsylvania, a PhD from the University of Cambridge, and a BSc in Chemistry from Imperial College London (first class honours). He holds an MBA from the University of Bath. Over his career in big pharma, he has been involved in hundreds of drug discovery projects. He executed Sanofi’s Lab031 partnership with Evotec, Sanofi’s natural product partnership with the Fraunhofer Institute, been part of the negotiating teams for the divestment of the Toulouse and Tucson Sanofi sites, and pioneered Sanofi’s risk-sharing approach to early drug discovery with academics and commercial partners, and he set up Sanofi’s partnerships in artificial intelligence for drug discovery. He has published numerous papers and patents and was co-editor of the textbook Small Molecule Medicinal Chemistry: Strategies and Technologies (Wiley).
Jens has more than 15 years of venture capital experience in biopharma and 10 years of operational experience in drug discovery and development. Jens is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare IT companies.
Before joining Apollo Ventures, Jens served as President of SR One for eight years. He is also co-founder and Managing Director of Action Potential Venture Capital (APVC). Previously, Jens was a General Partner at TVM Capital leading early-stage investments in Boston and was CEO and President of SelectX Pharmaceuticals. Before his investment career, Jens was leading research teams and pharma collaborations at Enanta Pharmaceuticals (NASDAQ: ENTA) and Mitotix.
Dr. Martin McMahon currently serves as the Cumming-Presidential Chair of Cancer Biology in the Dept. of Dermatology at the University of Utah, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute.
Dr. McMahon’s translational cancer research program focuses on the mechanisms underlying the initiation, progression and maintenance of metastatic melanoma, lung and pancreatic cancer. Although these malignancies are derived from distinctly different cell types, they share a striking number of common genetic alterations, especially mutations in the KRAS, BRAF or PIK3CA proto-oncogenes. To do this, Dr. McMahon’s laboratory uses genetically engineered mouse models, patient-derived xenografts and cultured cancer-derived cell lines.
Andrew Thorburn trained at the Universities of Glasgow, Oxford and University of California San Diego. He is currently at the University of Colorado where he is Professor and Chair of the Department of Pharmacology. Dr. Thorburn is an author of more than 150 scientific publications and has held multiple research grants from NIH and other agencies. The Thorburn lab studies autophagy’s roles in cell death and cancer therapy.
Sean M. Smith, Ph.D. is an Executive Director of Neuroscience Discovery at Merck in West Point, PA. In this role, he directs research for Neurodegenerative disease from target identification to early clinical development. He also leads efforts to identify and translate target engagement and disease progression biomarkers for neurological disorders. Prior to leading the Neurodegeneration department, Sean lead the Psychiatric Disorders department and was the chair of early clinical development teams for MK-8189 (Phase 2, schizophrenia) and MK-8719 (Phase 1, PSP). Sean did his postdoctoral training at the Salk Institute for Biological Studies in the laboratory of Dr Wylie Vale and received his Ph.D. in Neuroscience from the University of Illinois at Urbana-Champaign.
Dr. Evris Gavathiotis is a Professor of Biochemistry and Medicine at Albert Einstein College of Medicine and faculty member of the Albert Einstein Cancer Center and the Institute for Aging Research among others. His research focuses on mechanisms and protein interactions in cell death and cell survival signaling and the discovery and optimization of small molecule modulators towards novel chemical tools and therapeutics.
Fiona currently leads an Alzheimer’s Disease drug discovery team working on targets in protein degradation and homeostasis with a focus on tau biology. Her career has been dedicated to understanding the underlying mechanisms of neurodegeneration. Prior to joining Lilly she worked at University of Cambridge in the lab of Prof. David Rubinsztein studying the potential for autophagy modulation as a therapeutic target for neurodegenerative as well as the contribution of autophagy perturbation to the underlying pathogenesis in neurodegenerative diseases.
The Murthy lab’s research interests span innate immunity, human genetics and protein homeostasis. Given its emergent relevance to human disease, investigating the mechanisms by which autophagy controls inflammation is a major focus area. The Murthy lab utilizes functional genomics and proteomics to reveal therapeutically relevant immuno-modulatory pathways regulated by autophagy.
John Skidmore is a chemist by training, receiving a BA and DPhil from the University of Oxford. Following a post doc at the University of Liverpool with Prof Stan Roberts, John joined GSK where he worked as a medicinal chemist and project leader in the pain and neurodegeneration therapeutic areas. In 2010 John moved to the University of Cambridge, where, funded through the Wellcome Trust’s Seeding Drug Discovery scheme, he led a number of protein-protein interaction inhibitor projects. In 2015 John moved within the University, to his present position as the CSO of the Alzheimer’s Research UK Cambridge Drug Discovery Institute.
Andrew Nichols, Ph.D., is Chief Scientific Officer at Catabasis Pharmaceuticals, a rare disease-focused biotechnology company in Boston, MA. Andy is responsible for setting overall scientific strategy and leading all research, drug discovery, nonclinical and product development activities through a combination of in-house and external activities.
Jay Debnath is Distinguished Professor and Chair of Pathology at the University of California, San Francisco. His laboratory is widely recognized for its expertise on the diverse cell biological roles of autophagy during cancer progression and metastasis. Recently, he has been illuminating how the autophagy pathway orchestrates secretory and exocytic functions distinct from its long-recognized roles in catabolism.
Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.
After his career in CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992), he held senior positions at Almirall, SA (1992-2003) as Manager and Head of Business Development and Licensing and Lacer, SA (2005-2007) as Director, Business Development and Licensing.
Carles has also 4 years experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.
In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009
Christian Peters, MD, PhD, is CEO and President of Pinpoint Therapeutics, Inc. and serves on its Board of Directors. Christian has over 29 years’ experience, including 19 years of successful clinical development and commercialization in a number of senior leadership positions in the pharmaceutical industry, and more than 10 years of clinical and research experience in academic settings. Before this, Christian was the CMO for Realm Therapeutics and Therakos.
Prior to joining Therakos, Dr. Peters served at CSL Behring and its predecessor companies in multiple positions with increasing responsibilities in Clinical Development, Regulatory and Medical Affairs. At CSL Behring, Dr. Peters led or participated in teams that secured FDA approval for seven products.
Prior to his years in Industry, he was a National Research Service Award (NRSA) Fellow at the University of Pennsylvania, a Fogarty International Fellow at the National Institutes of Health (NIH), and a Resident at the University of Berlin in Germany after here earning his MD and PhD.
Christian Peters has been awarded NIH and other grants, has published in peer-reviewed journals, and holds five patents.
James Duce obtained his Ph.D from Cardiff University in the neurobiology of Huntington’s disease. He broadened his neurodegenerative disease research knowledge through postdoctoral studies with Prof Carmela Abraham in Boston USA and Profs Colin Masters and Ashley Bush in Melbourne, Australia. His return to the UK in 2012, supported through an Alzheimer’s Research UK Senior Fellowship, enabled him to run a team at University of Leeds that validated several post-translational modifications as disease targets. He has subsequently led several internationally funded translational projects in neurodegenerative disease. James joined the ALBORADA Drug Discovery Institute as Head of Biology in 2017.
Vojo Deretic, Ph.D., is the department chair of the Department of Molecular Genetics and Microbiology at the University of New Mexico School of Medicine and the director of the NIH-funded Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence. The AIM center aims to promote autophagy research nationally and internationally as well as to develop a cadre of junior faculty along with senior experts in this area to study fundamental mechanisms and how autophagy intersects with a broad spectrum of human disease and health states. Dr. Deretic received his undergraduate, graduate and postdoctoral education in Belgrade, Paris, and Chicago. His main contributions to science come from studies by his team on the role of autophagy in infection and immunity. Recently, his group has become interested in the specific connections between metabolic roles of autophagy and its quality control functions.
After having spent 12 years in Pharma Development at Sanofi and developed several drugs in Neurology and Oncology as Project manager, Agnès Menut has put in place a Business Development department in an Immunotherapy service platform and is now managing the partnering within Genoscience Pharma.
Genoscience Pharma is a clinical-stage French biotech company, focusing for several years on Autophagy. Genoscience has recently finalized its phase 1b in Hepatocarcinomas and pancreatic cancers with its lead compound GNS561, a ppt1 inhibitor.
Today, in addition to cancerology, GNS561 represents a new hope also in Covid-19 treatment and will be tested in a phase 2 in moderate Covid-19 patients.
Digital Conference Platform
The Digital conference platform is purpose-built to enable us to provide you with a more personal experience.
For starters, no more wondering who is in the room! View and message the entire attendee list. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning. Through an engaging and interactive agenda, you will be able to actively or passively participate as much as you’d like. From polls and Q&A through to open discussions and dynamic panels, it has never been easier to accelerate your knowledge of how to drug Autophagy-driven diseases.
Imagine the possibilities of this digital event! Networking with your peers, learning from the experts, collaborating, and shaping the future of the Drugging Autophagy industry – all on a world-class, purpose-built platform.
Partner with Us
The Drugging Autophagy Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together leading academics and foremost industry experts.
Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.
No need to sit behind a desk! Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.
Get in touch to learn more about the options available at The Drugging Autophagy Summit.
Register for the Event
For pricing and booking options please click the button to go to the registration page.